Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

This study has been completed.

Study NCT00026169 Information provided by Case Comprehensive Cancer Center

First Received: November 9, 2001 Last Updated: June 9, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2008
Primary Completion Date:	April 2005 (Final data collection date for primary outcome measure)

Publications:

Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC; National Cancer Institute Organ Dysfunction Working Group. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008 Feb 1;26(4):570-6.

Remick SC, Ramanathan RK, Mulkerin D, et al.: P-5340: a phase I pharmacokinetic study of STI-571 in patients (pts) with advanced malignancies and varying degrees of renal dysfunction. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-503, 2003.